Equities

Checkmate Pharmaceuticals Inc

CMPI:NMQ

Checkmate Pharmaceuticals Inc

Actions
  • Price (USD)14.90
  • Today's Change0.89 / 6.35%
  • Shares traded39.82k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jan 22 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. Its product candidate, CMP-001, is a differentiated Toll-like receptor 9 (TLR9), agonist delivered as a biologic virus-like particle (VLP), utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. The Company is also developing CMP-001 in combination with several checkpoint inhibitor immunotherapies in melanoma and head and neck cancer.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2015
  • Employees22.00
  • Location
    Checkmate Pharmaceuticals Inc245 Main Street, 2Nd FloorCAMBRIDGE 02142United StatesUSA
  • Phone+1 (978) 503-2124
  • Fax+1 (302) 655-5049
  • Websitehttp://checkmatepharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cerecor Inc5.78m-53.88m305.28m18.00--6.80--52.79-0.9193-0.73870.09860.51490.09941.291.75321,290.60-92.58-39.12-130.53-59.3195.40---931.58-150.752.48--0.00---3.96--55.94--68.13--
Vistagen Therapeutics Inc334.00k-16.98m306.18m9.00--38.77--916.71-0.3437-0.34370.00640.05710.023----37,111.11-107.93-354.97-145.02-755.47-----4,686.47-9,374.84---1,757.490.0953------14.35------
CytomX Therapeutics Inc92.27m-53.64m307.39m158.00--6.40--3.33-1.17-1.172.011.040.2468--335.52583,974.70-14.35-24.00-18.84-29.18-----58.14-165.55----0.00---3.3862.48-20.84--16.03--
Galecto Inc0.00-56.73m309.95m23.00---------2.29-2.290.003.53---------------------------29.090.00-------121.35------
Matinas BioPharma Holdings Inc95.83k-22.49m311.13m21.00--4.83--3,246.68-0.1207-0.12070.00050.34280.0016----4,563.33-36.25-85.60-37.98-97.81-----22,622.13-11,499.32----0.0009---25.00---22.08--7.05--
Alpine Immune Sciences Inc4.58m-27.74m312.30m53.00--4.63--68.25-1.44-1.440.23452.830.0418--1.7886,339.63-25.36-26.54-32.78-28.85-----606.16-1,154.15---101.750.1298--146.81---14.70--188.61--
NuCana PLC (ADR)0.00-35.75m314.13m31.00--2.08-----1.08-1.080.002.950.00----0.00-26.69---28.83-------------25.300.0065-------54.71------
Vyne Therapeutics Inc16.71m-253.89m315.61m180.00--6.37--18.89-3.19-3.190.17910.2950.1636----417,675.00-248.59---295.88--94.86---1,519.63--3.95-154.140.40---100.00---43.27------
Natures Sunshine Products Inc375.16m16.47m317.48m834.0019.392.1511.170.84630.83280.832818.997.511.662.1245.57449,828.507.750.424610.860.607673.6873.664.670.24451.48--0.0302216.57-0.7113-0.2277892.15-19.47-27.95--
Checkmate Pharmaceuticals Inc-100.00bn-100.00bn321.10m22.00--2.37----------6.27----------------------------0.00-------39.48------
Verrica Pharmaceuticals Inc0.00-37.35m326.94m17.00--8.34-----1.50-1.500.001.510.00----0.00-47.89---66.30-------------29.740.4717-------36.61------
Concert Pharmaceuticals Inc7.91m-72.86m331.01m70.00--2.52--41.86-2.57-2.570.27284.290.0518--112.17112,971.40-47.73-8.54-51.27-9.08-----921.38-29.27---83.440.00---89.75-33.96-39.52---3.15--
Fortress Biotech Inc42.98m-56.72m331.71m93.00--3.42--7.72-0.853-0.8530.6421.040.166113.924.13462,150.50-44.62-54.56-75.68-104.8267.72---268.61-463.976.35-6.660.2464--36.26--45.27------
Ampio Pharmaceuticals Inc0.00-12.30m333.10m23.00--30.87-----0.0745-0.07450.000.05830.00----0.00-78.07-55.21-90.41-63.40------------0.00-------140.10---69.74--
MEI Pharma Inc31.59m-45.11m336.44m51.00--4.09--10.65-0.5196-0.51960.32560.73170.2233--10.80619,411.80-31.89-28.33-37.38-31.8192.11---142.81-206.30---1.560.00--488.26---173.60--126.49--
Data as of Jan 22 2021. Currency figures normalised to Checkmate Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

13.08%Per cent of shares held by top holders
HolderShares% Held
Clough Capital Partners LPas of 09 Nov 20201.33m6.18%
Sectoral Asset Management, Inc.as of 30 Sep 2020600.69k2.79%
DWS Investment GmbHas of 30 Sep 2020250.00k1.16%
BlackRock Fund Advisorsas of 30 Sep 2020211.79k0.98%
Ensign Peak Advisors, Inc.as of 30 Sep 2020119.92k0.56%
Millennium Management LLCas of 30 Sep 2020109.07k0.51%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202055.64k0.26%
The Vanguard Group, Inc.as of 30 Sep 202055.22k0.26%
CaaS Capital Management LPas of 30 Sep 202044.97k0.21%
SSgA Funds Management, Inc.as of 30 Sep 202039.05k0.18%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.